| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 13 | 2021 | 349 | 3.95 | Why? |
| HIV Antibodies | 13 | 2019 | 776 | 2.99 | Why? |
| HIV-1 | 19 | 2019 | 3365 | 2.02 | Why? |
| Orthomyxoviridae | 4 | 2017 | 1168 | 1.46 | Why? |
| Immunoglobulin Fc Fragments | 4 | 2021 | 691 | 1.37 | Why? |
| AIDS Vaccines | 6 | 2019 | 452 | 1.35 | Why? |
| Receptors, IgG | 4 | 2021 | 578 | 1.25 | Why? |
| HIV Infections | 22 | 2019 | 11620 | 1.09 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 3 | 2017 | 154 | 1.03 | Why? |
| Influenza Vaccines | 5 | 2021 | 2941 | 0.99 | Why? |
| Phagocytosis | 4 | 2021 | 409 | 0.97 | Why? |
| Receptors, Fc | 4 | 2018 | 153 | 0.97 | Why? |
| Simian Immunodeficiency Virus | 3 | 2017 | 251 | 0.96 | Why? |
| Antibodies, Neutralizing | 18 | 2021 | 25288 | 0.82 | Why? |
| Orthomyxoviridae Infections | 4 | 2021 | 1001 | 0.75 | Why? |
| Antibody Formation | 6 | 2021 | 4038 | 0.65 | Why? |
| Heterosexuality | 1 | 2017 | 148 | 0.64 | Why? |
| Sulfhydryl Compounds | 1 | 2017 | 104 | 0.62 | Why? |
| Antibodies, Viral | 19 | 2021 | 51949 | 0.59 | Why? |
| T-Lymphocytes, Helper-Inducer | 6 | 2021 | 497 | 0.58 | Why? |
| Immunity, Cellular | 4 | 2021 | 3614 | 0.51 | Why? |
| Immunologic Memory | 4 | 2021 | 3362 | 0.49 | Why? |
| Macaca | 6 | 2021 | 388 | 0.47 | Why? |
| Receptors, Antigen, T-Cell | 3 | 2021 | 760 | 0.44 | Why? |
| HLA-A2 Antigen | 2 | 2021 | 134 | 0.41 | Why? |
| Immunodominant Epitopes | 3 | 2021 | 813 | 0.39 | Why? |
| Nanoparticles | 5 | 2021 | 2040 | 0.39 | Why? |
| SAIDS Vaccines | 1 | 2008 | 25 | 0.37 | Why? |
| Immunity, Humoral | 3 | 2019 | 4849 | 0.36 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2021 | 511 | 0.36 | Why? |
| CD8-Positive T-Lymphocytes | 8 | 2021 | 5837 | 0.34 | Why? |
| Germinal Center | 2 | 2021 | 332 | 0.33 | Why? |
| Influenza, Human | 5 | 2021 | 10779 | 0.32 | Why? |
| West Nile virus | 1 | 2008 | 206 | 0.31 | Why? |
| Replicon | 1 | 2008 | 232 | 0.31 | Why? |
| B-Lymphocytes | 6 | 2021 | 4418 | 0.30 | Why? |
| Animals | 28 | 2021 | 78931 | 0.30 | Why? |
| Virus Latency | 2 | 2017 | 251 | 0.29 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.27 | Why? |
| Killer Cells, Natural | 6 | 2019 | 2093 | 0.26 | Why? |
| Interferon Type I | 1 | 2017 | 2789 | 0.26 | Why? |
| Aging | 1 | 2018 | 3581 | 0.23 | Why? |
| Viremia | 3 | 2018 | 1020 | 0.23 | Why? |
| HLA-A24 Antigen | 1 | 2021 | 18 | 0.23 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.21 | Why? |
| Hemagglutinins | 1 | 2021 | 143 | 0.20 | Why? |
| Neutralization Tests | 4 | 2021 | 6698 | 0.20 | Why? |
| HIV | 2 | 2017 | 1116 | 0.20 | Why? |
| Dimerization | 1 | 2021 | 475 | 0.20 | Why? |
| HIV Seropositivity | 2 | 2019 | 320 | 0.19 | Why? |
| Liposomes | 1 | 2021 | 334 | 0.18 | Why? |
| Binding Sites, Antibody | 2 | 2017 | 466 | 0.18 | Why? |
| Gene Products, env | 1 | 2018 | 74 | 0.18 | Why? |
| Human Immunodeficiency Virus Proteins | 1 | 2017 | 20 | 0.18 | Why? |
| CD4-Positive T-Lymphocytes | 7 | 2021 | 4545 | 0.18 | Why? |
| Disease Models, Animal | 5 | 2020 | 10998 | 0.18 | Why? |
| Sezary Syndrome | 1 | 2017 | 30 | 0.17 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2017 | 191 | 0.17 | Why? |
| HIV Antigens | 1 | 2018 | 102 | 0.17 | Why? |
| Hydroxamic Acids | 1 | 2017 | 43 | 0.17 | Why? |
| Polymerization | 1 | 2017 | 46 | 0.17 | Why? |
| Epitopes | 3 | 2020 | 4113 | 0.17 | Why? |
| Receptors, CCR5 | 1 | 2019 | 186 | 0.17 | Why? |
| Humans | 56 | 2021 | 930598 | 0.17 | Why? |
| HLA-B Antigens | 1 | 2018 | 166 | 0.16 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 386 | 0.16 | Why? |
| Depsipeptides | 1 | 2017 | 61 | 0.16 | Why? |
| Alemtuzumab | 1 | 2017 | 121 | 0.16 | Why? |
| Antibody-Dependent Enhancement | 1 | 2020 | 413 | 0.16 | Why? |
| Vaccines, Synthetic | 2 | 2016 | 3231 | 0.16 | Why? |
| HIV Core Protein p24 | 1 | 2016 | 48 | 0.16 | Why? |
| HIV Integrase Inhibitors | 1 | 2018 | 173 | 0.16 | Why? |
| Immunity, Mucosal | 2 | 2018 | 426 | 0.15 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.15 | Why? |
| Virus Activation | 2 | 2017 | 480 | 0.15 | Why? |
| Polyethylene Glycols | 2 | 2017 | 574 | 0.15 | Why? |
| Polymers | 2 | 2017 | 507 | 0.15 | Why? |
| Epitopes, T-Lymphocyte | 3 | 2021 | 2262 | 0.15 | Why? |
| Cytotoxicity, Immunologic | 1 | 2017 | 287 | 0.15 | Why? |
| Complement System Proteins | 1 | 2019 | 380 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.14 | Why? |
| Single-Chain Antibodies | 1 | 2017 | 259 | 0.14 | Why? |
| Biotechnology | 1 | 2018 | 444 | 0.14 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2018 | 572 | 0.14 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.14 | Why? |
| Protein Processing, Post-Translational | 1 | 2018 | 634 | 0.14 | Why? |
| Single-Domain Antibodies | 1 | 2021 | 744 | 0.13 | Why? |
| Semen | 1 | 2019 | 550 | 0.13 | Why? |
| Life Expectancy | 1 | 2018 | 474 | 0.13 | Why? |
| Vaccines, Inactivated | 2 | 2018 | 1562 | 0.13 | Why? |
| Macaca nemestrina | 2 | 2015 | 71 | 0.13 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2017 | 492 | 0.13 | Why? |
| Immunoassay | 2 | 2020 | 4485 | 0.12 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.12 | Why? |
| Cell Line, Tumor | 1 | 2021 | 3608 | 0.12 | Why? |
| Viral Regulatory and Accessory Proteins | 1 | 2017 | 482 | 0.12 | Why? |
| Cell Survival | 1 | 2017 | 1581 | 0.12 | Why? |
| Bronchi | 1 | 2019 | 1048 | 0.12 | Why? |
| Nanotechnology | 1 | 2018 | 821 | 0.12 | Why? |
| Lectins, C-Type | 1 | 2015 | 405 | 0.11 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2017 | 2984 | 0.11 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.11 | Why? |
| Histocompatibility Antigens Class I | 2 | 2018 | 624 | 0.11 | Why? |
| Genetic Engineering | 2 | 2016 | 325 | 0.11 | Why? |
| Nanostructures | 1 | 2018 | 700 | 0.11 | Why? |
| Antibodies, Monoclonal | 3 | 2020 | 8041 | 0.10 | Why? |
| Immunoglobulin A | 2 | 2021 | 3567 | 0.10 | Why? |
| Mice | 5 | 2021 | 21357 | 0.10 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2017 | 830 | 0.10 | Why? |
| Australia | 3 | 2018 | 6306 | 0.10 | Why? |
| Spike Glycoprotein, Coronavirus | 6 | 2021 | 37182 | 0.10 | Why? |
| Peptidyl-Dipeptidase A | 2 | 2021 | 9659 | 0.10 | Why? |
| Fusion Proteins, gag-pol | 1 | 2008 | 6 | 0.09 | Why? |
| Vaccines | 2 | 2019 | 3692 | 0.09 | Why? |
| Lymphocyte Activation | 3 | 2020 | 2742 | 0.09 | Why? |
| Anaphylaxis | 1 | 2018 | 940 | 0.09 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.09 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.09 | Why? |
| Antibodies | 1 | 2015 | 846 | 0.09 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.08 | Why? |
| Influenza A virus | 1 | 2019 | 2234 | 0.08 | Why? |
| Antigens, Viral | 3 | 2020 | 6298 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Communicable Diseases | 1 | 2021 | 2148 | 0.08 | Why? |
| Dendritic Cells | 1 | 2015 | 1330 | 0.08 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.07 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.07 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.07 | Why? |
| Mutation, Missense | 1 | 2011 | 863 | 0.07 | Why? |
| Models, Immunological | 2 | 2021 | 727 | 0.07 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.07 | Why? |
| Mucous Membrane | 2 | 2018 | 305 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Neutrophils | 2 | 2019 | 5476 | 0.07 | Why? |
| Models, Theoretical | 2 | 2021 | 6659 | 0.07 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.07 | Why? |
| Protein Binding | 2 | 2018 | 11430 | 0.07 | Why? |
| Immunophenotyping | 2 | 2020 | 1290 | 0.07 | Why? |
| Vaccination | 3 | 2019 | 19050 | 0.07 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2017 | 1679 | 0.06 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2018 | 2523 | 0.06 | Why? |
| Adjuvants, Immunologic | 3 | 2019 | 1709 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Mice, Inbred BALB C | 3 | 2021 | 5814 | 0.06 | Why? |
| Viral Vaccines | 2 | 2021 | 7560 | 0.06 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Receptors, CXCR3 | 1 | 2021 | 159 | 0.05 | Why? |
| Male | 11 | 2021 | 367725 | 0.05 | Why? |
| Flow Cytometry | 2 | 2021 | 2393 | 0.05 | Why? |
| Antigenic Variation | 1 | 2021 | 249 | 0.05 | Why? |
| Macrophage Inflammatory Proteins | 1 | 2019 | 14 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Viral Load | 5 | 2018 | 15850 | 0.05 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 203 | 0.05 | Why? |
| Camelids, New World | 1 | 2021 | 276 | 0.05 | Why? |
| Leukocytes, Mononuclear | 2 | 2020 | 2115 | 0.05 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.05 | Why? |
| Virus Replication | 2 | 2018 | 14331 | 0.05 | Why? |
| Chemokines, CC | 1 | 2019 | 79 | 0.05 | Why? |
| Terminal Repeat Sequences | 1 | 2018 | 13 | 0.05 | Why? |
| Amino Acid Motifs | 1 | 2021 | 620 | 0.05 | Why? |
| Interleukin-18 | 1 | 2021 | 328 | 0.05 | Why? |
| HL-60 Cells | 1 | 2018 | 60 | 0.05 | Why? |
| Viral Core Proteins | 1 | 2019 | 134 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2019 | 11041 | 0.05 | Why? |
| Chemokine CCL5 | 1 | 2019 | 169 | 0.05 | Why? |
| Phenotype | 2 | 2021 | 4037 | 0.05 | Why? |
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 52 | 0.05 | Why? |
| Cytotoxicity Tests, Immunologic | 1 | 2017 | 32 | 0.05 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Cell Degranulation | 1 | 2018 | 130 | 0.04 | Why? |
| Antibody-Producing Cells | 1 | 2018 | 66 | 0.04 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.04 | Why? |
| HIV Long-Term Survivors | 1 | 2017 | 56 | 0.04 | Why? |
| NLR Proteins | 1 | 2017 | 23 | 0.04 | Why? |
| Polyproteins | 1 | 2020 | 814 | 0.04 | Why? |
| Information Services | 1 | 2018 | 70 | 0.04 | Why? |
| Protein Isoforms | 1 | 2018 | 347 | 0.04 | Why? |
| Adaptive Immunity | 2 | 2021 | 2585 | 0.04 | Why? |
| Silicon Dioxide | 1 | 2017 | 131 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Genetic Loci | 1 | 2018 | 439 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.04 | Why? |
| T-Lymphocytes | 2 | 2019 | 6670 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| Aged | 5 | 2021 | 215776 | 0.04 | Why? |
| Female | 9 | 2021 | 380317 | 0.04 | Why? |
| Tissue Distribution | 1 | 2017 | 483 | 0.04 | Why? |
| Stochastic Processes | 1 | 2017 | 369 | 0.04 | Why? |
| Vaccines, Virus-Like Particle | 1 | 2019 | 312 | 0.04 | Why? |
| Fluorescent Antibody Technique | 1 | 2018 | 835 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Surface Plasmon Resonance | 1 | 2017 | 440 | 0.04 | Why? |
| Proof of Concept Study | 1 | 2017 | 696 | 0.04 | Why? |
| CD8 Antigens | 1 | 2015 | 72 | 0.04 | Why? |
| Placebos | 1 | 2018 | 629 | 0.04 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.04 | Why? |
| Mast Cells | 1 | 2018 | 370 | 0.04 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.04 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.04 | Why? |
| Th1 Cells | 1 | 2021 | 1228 | 0.03 | Why? |
| Lipids | 1 | 2021 | 1079 | 0.03 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.03 | Why? |
| Toll-Like Receptors | 1 | 2017 | 365 | 0.03 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| Cancer Vaccines | 1 | 2015 | 136 | 0.03 | Why? |
| Vagina | 1 | 2016 | 327 | 0.03 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 552 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.03 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.03 | Why? |
| Safety | 1 | 2020 | 1583 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2021 | 1783 | 0.03 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.03 | Why? |
| Gene Products, gag | 1 | 2011 | 28 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2020 | 1061 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.03 | Why? |
| Cell Line | 2 | 2018 | 12040 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.03 | Why? |
| Ferrets | 1 | 2017 | 1201 | 0.03 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Protein Conformation | 1 | 2021 | 4386 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2016 | 952 | 0.03 | Why? |
| Mice, Inbred C57BL | 1 | 2021 | 5542 | 0.03 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.02 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.02 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.02 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Peptide Fragments | 1 | 2020 | 2075 | 0.02 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Swine | 1 | 2018 | 3352 | 0.02 | Why? |
| Swine Diseases | 1 | 2018 | 1219 | 0.02 | Why? |
| Virion | 1 | 2017 | 1444 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.02 | Why? |
| Immunization, Secondary | 1 | 2016 | 1649 | 0.02 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Immunomodulation | 1 | 2017 | 1472 | 0.02 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Selection, Genetic | 1 | 2011 | 691 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.02 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.02 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Amino Acid Substitution | 1 | 2011 | 1706 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2019 | 4624 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.01 | Why? |
| Information Dissemination | 1 | 2018 | 2986 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Models, Statistical | 1 | 2017 | 5312 | 0.01 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.01 | Why? |
| Lung | 2 | 2017 | 31049 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Public Health | 1 | 2019 | 16359 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Neoplasms | 1 | 2015 | 17251 | 0.00 | Why? |